Formycon AG
XETRA:FYB

Watchlist Manager
Formycon AG Logo
Formycon AG
XETRA:FYB
Watchlist
Price: 52.5 EUR 2.34%
Market Cap: 927.2m EUR
Have any thoughts about
Formycon AG?
Write Note

Formycon AG
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Formycon AG
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Formycon AG
XETRA:FYB
Total Current Liabilities
€69.3m
CAGR 3-Years
107%
CAGR 5-Years
65%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Total Current Liabilities
€2.1B
CAGR 3-Years
51%
CAGR 5-Years
75%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Total Current Liabilities
€487.8m
CAGR 3-Years
34%
CAGR 5-Years
59%
CAGR 10-Years
31%
CureVac NV
NASDAQ:CVAC
Total Current Liabilities
€186.4m
CAGR 3-Years
-9%
CAGR 5-Years
46%
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Total Current Liabilities
€156.6m
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Total Current Liabilities
€277.1m
CAGR 3-Years
39%
CAGR 5-Years
22%
CAGR 10-Years
8%
No Stocks Found

Formycon AG
Glance View

Market Cap
927m EUR
Industry
Biotechnology

Formycon AG engages in the manufacture of biosimilar drugs and formulations. The company is headquartered in Martinsried, Bayern and currently employs 159 full-time employees. The company went IPO on 2010-12-20. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The firm focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.

FYB Intrinsic Value
77.46 EUR
Undervaluation 32%
Intrinsic Value
Price

See Also

What is Formycon AG's Total Current Liabilities?
Total Current Liabilities
69.3m EUR

Based on the financial report for Dec 31, 2023, Formycon AG's Total Current Liabilities amounts to 69.3m EUR.

What is Formycon AG's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
65%

Over the last year, the Total Current Liabilities growth was 37%. The average annual Total Current Liabilities growth rates for Formycon AG have been 107% over the past three years , 65% over the past five years .

Back to Top